Compensatory intestinal immunoglobulin response after vancomycin treatment in humans.


Journal

Gut microbes
ISSN: 1949-0984
Titre abrégé: Gut Microbes
Pays: United States
ID NLM: 101495343

Informations de publication

Date de publication:
Historique:
entrez: 21 1 2021
pubmed: 22 1 2021
medline: 15 1 2022
Statut: ppublish

Résumé

Intestinal immunoglobulins (Ig) are abundantly secreted antibodies that bind bacteria and bacterial components in the gut. This binding is considered to accelerate bacterial transit time and prevent the interaction of potentially immunogenic compounds with intestinal immune cells. Ig secretion is regulated by alterations in gut microbiome composition, an event rarely mapped in an intervention setting in humans. Here, we determined the intestinal and systemic Ig response to a major intervention in gut microbiome composition. Healthy humans and humans with metabolic syndrome received oral vancomycin 500 mg four times per day for 7 days. Coinciding with a vancomycin-induced increase in Gram-negative bacteria, fecal levels of the immunogenic bacterial components lipopolysaccharide (LPS) and flagellin drastically increased. Intestinal antibodies (IgA and IgM) significantly increased, whereas peripheral antibodies (IgG, IgA, and IgM) were mostly unaffected by vancomycin treatment. Bacterial cell sorting followed by 16S rRNA sequencing revealed that the majority of Gram-negative bacteria, including opportunistic pathogens, were IgA-coated after the intervention. We suggest that the intestinal Ig response after vancomycin treatment prevents the intrusion of pathogens and bacterial components into systemic sites.

Identifiants

pubmed: 33475461
doi: 10.1080/19490976.2021.1875109
pmc: PMC7833805
doi:

Substances chimiques

Immunoglobulins 0
Lipopolysaccharides 0
Flagellin 12777-81-0
Vancomycin 6Q205EH1VU

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-14

Références

J Lipid Res. 2009 Jan;50(1):90-7
pubmed: 18815435
PLoS One. 2013 Apr 22;8(4):e61217
pubmed: 23630581
Nucleic Acids Res. 2013 Jan;41(Database issue):D590-6
pubmed: 23193283
Science. 2017 Oct 20;358(6361):
pubmed: 28971969
Immunity. 2018 Aug 21;49(2):211-224
pubmed: 30134201
Cell. 2014 Aug 28;158(5):1000-1010
pubmed: 25171403
Mucosal Immunol. 2020 Jan;13(1):12-21
pubmed: 31740744
Nat Rev Immunol. 2014 Oct;14(10):667-85
pubmed: 25234148
J Antimicrob Chemother. 2017 Jan;72(1):128-136
pubmed: 27707993
Cell. 2016 May 5;165(4):842-53
pubmed: 27133167
Clin Microbiol Rev. 2007 Oct;20(4):593-621
pubmed: 17934076
Nature. 2008 Oct 9;455(7214):804-7
pubmed: 18724361
Front Microbiol. 2011 Aug 01;2:166
pubmed: 21904534
Appl Environ Microbiol. 2013 Sep;79(17):5112-20
pubmed: 23793624
J Antimicrob Chemother. 2007 May;59(5):900-12
pubmed: 17369278
Diabetes. 2008 Jun;57(6):1470-81
pubmed: 18305141
Cell Microbiol. 2009 Jul;11(7):1034-43
pubmed: 19374653
Curr Opin Microbiol. 2013 Jun;16(3):255-61
pubmed: 23831042
Trends Microbiol. 2018 May;26(5):423-435
pubmed: 29173868
Front Microbiol. 2019 Dec 17;10:2865
pubmed: 31921045
Annu Rev Immunol. 2011;29:415-45
pubmed: 21219177
Nat Med. 2016 Jul 7;22(7):713-22
pubmed: 27387886
Nature. 2016 May 25;534(7606):263-6
pubmed: 27279225
World J Gastroenterol. 2014 Dec 7;20(45):16795-810
pubmed: 25492994
Exp Mol Med. 2017 Sep 1;49(9):e373
pubmed: 28860663
Cell Host Microbe. 2020 Mar 11;27(3):467-475.e6
pubmed: 32075742
Nat Biotechnol. 2017 Nov;35(11):1069-1076
pubmed: 28967887
Microorganisms. 2019 Jan 10;7(1):
pubmed: 30634578
Am J Clin Nutr. 2007 Nov;86(5):1286-92
pubmed: 17991637
Trends Microbiol. 2019 Jan;27(1):17-25
pubmed: 30219265
Sci Rep. 2019 Sep 19;9(1):13574
pubmed: 31537840
Appl Environ Microbiol. 2007 Aug;73(16):5261-7
pubmed: 17586664
Nat Commun. 2019 Dec 11;10(1):5650
pubmed: 31827095
Bioinformatics. 2010 Oct 1;26(19):2460-1
pubmed: 20709691
Gut. 2018 Dec;67(12):2213-2222
pubmed: 30194220
PLoS Comput Biol. 2017 Nov 3;13(11):e1005752
pubmed: 29099853
Immunity. 2015 Sep 15;43(3):541-53
pubmed: 26320660
Sci Transl Med. 2015 Feb 25;7(276):276ra24
pubmed: 25717097
Metabolism. 2017 Mar;68:133-144
pubmed: 28183445
Diabetes. 2007 Jul;56(7):1761-72
pubmed: 17456850
Int J Lab Hematol. 2013 Dec;35(6):644-51
pubmed: 23663689
J Infect Dis. 2010 Feb 15;201(4):534-43
pubmed: 20064069
Mol Microbiol. 1998 Oct;30(2):285-93
pubmed: 9791174
Physiol Rep. 2019 Aug;7(16):e14199
pubmed: 31423751
Nature. 2015 May 7;521(7550):90-93
pubmed: 25686606
Diabetes Care. 2011 Feb;34(2):392-7
pubmed: 21270197
Trends Microbiol. 2014 Sep;22(9):517-27
pubmed: 24894628

Auteurs

Torsten P M Scheithauer (TPM)

Department of Experimental Vascular Medicine, Amsterdam UMC, Location AMC at University of Amsterdam , Amsterdam, The Netherlands.
Department of Internal Medicine, Diabetes Center, Amsterdam UMC, Location VUmc at Vrije Universiteit Amsterdam , Amsterdam, The Netherlands.

Guido J Bakker (GJ)

Department of Experimental Vascular Medicine, Amsterdam UMC, Location AMC at University of Amsterdam , Amsterdam, The Netherlands.

Maaike Winkelmeijer (M)

Department of Experimental Vascular Medicine, Amsterdam UMC, Location AMC at University of Amsterdam , Amsterdam, The Netherlands.

Mark Davids (M)

Department of Experimental Vascular Medicine, Amsterdam UMC, Location AMC at University of Amsterdam , Amsterdam, The Netherlands.

Max Nieuwdorp (M)

Department of Experimental Vascular Medicine, Amsterdam UMC, Location AMC at University of Amsterdam , Amsterdam, The Netherlands.
Department of Internal Medicine, Diabetes Center, Amsterdam UMC, Location VUmc at Vrije Universiteit Amsterdam , Amsterdam, The Netherlands.

Daniël H van Raalte (DH)

Department of Experimental Vascular Medicine, Amsterdam UMC, Location AMC at University of Amsterdam , Amsterdam, The Netherlands.
Department of Internal Medicine, Diabetes Center, Amsterdam UMC, Location VUmc at Vrije Universiteit Amsterdam , Amsterdam, The Netherlands.

Hilde Herrema (H)

Department of Experimental Vascular Medicine, Amsterdam UMC, Location AMC at University of Amsterdam , Amsterdam, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH